| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
|
J Natl Cancer Inst
|
2008
|
12.77
|
|
2
|
TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
|
N Engl J Med
|
2007
|
5.92
|
|
3
|
Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis.
|
J Clin Oncol
|
2008
|
4.39
|
|
4
|
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
|
Head Neck
|
2005
|
4.27
|
|
5
|
Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C.
|
Head Neck
|
2009
|
2.59
|
|
6
|
New directions in the systemic treatment of metastatic thyroid cancer.
|
Oncology (Williston Park)
|
2009
|
2.14
|
|
7
|
TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group.
|
Lancet Oncol
|
2007
|
2.03
|
|
8
|
Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11.
|
Arch Otolaryngol Head Neck Surg
|
2003
|
1.76
|
|
9
|
Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
|
J Clin Oncol
|
2005
|
1.63
|
|
10
|
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
|
Cancer Res
|
2004
|
1.55
|
|
11
|
Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
|
Cancer
|
2004
|
1.43
|
|
12
|
Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14).
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.18
|
|
13
|
Volumetric change of selected organs at risk during IMRT for oropharyngeal cancer.
|
Int J Radiat Oncol Biol Phys
|
2010
|
1.14
|
|
14
|
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
|
Clin Cancer Res
|
2003
|
1.10
|
|
15
|
CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.
|
Am J Surg Pathol
|
2005
|
1.04
|
|
16
|
Combined modality therapy of esophageal cancer.
|
J Natl Compr Canc Netw
|
2008
|
0.97
|
|
17
|
Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia.
|
Head Neck
|
2012
|
0.96
|
|
18
|
The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins.
|
Clin Cancer Res
|
2009
|
0.95
|
|
19
|
Overexpression of claudin proteins in esophageal adenocarcinoma and its precursor lesions.
|
Appl Immunohistochem Mol Morphol
|
2006
|
0.94
|
|
20
|
Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group.
|
Cancer
|
2009
|
0.94
|
|
21
|
Effect of radiotherapy and chemotherapy on the risk of mucositis during intensity-modulated radiation therapy for oropharyngeal cancer.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.94
|
|
22
|
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
|
Cancer Res
|
2006
|
0.93
|
|
23
|
Defining the risk of involvement for each neck nodal level in patients with early T-stage node-positive oropharyngeal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.92
|
|
24
|
Hypopharyngeal dose is associated with severe late toxicity in locally advanced head-and-neck cancer: an RTOG analysis.
|
Int J Radiat Oncol Biol Phys
|
2012
|
0.88
|
|
25
|
Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382).
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.83
|
|
26
|
Treatment of head and neck cancer.
|
N Engl J Med
|
2008
|
0.83
|
|
27
|
A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
|
Clin Cancer Res
|
2012
|
0.83
|
|
28
|
Volumetric change of human papillomavirus-related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy.
|
Head Neck
|
2012
|
0.83
|
|
29
|
Comparison of clinical and pathological staging in head and neck squamous cell carcinoma: results from Intergroup Study ECOG 4393/RTOG 9614.
|
Arch Otolaryngol Head Neck Surg
|
2009
|
0.82
|
|
30
|
Impact of gender, partner status, and race on locoregional failure and overall survival in head and neck cancer patients in three radiation therapy oncology group trials.
|
Int J Radiat Oncol Biol Phys
|
2011
|
0.81
|
|
31
|
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.
|
Int J Oncol
|
2010
|
0.78
|
|
32
|
Controversies in the management of advanced laryngeal squamous cell carcinoma.
|
Cancer
|
2004
|
0.75
|
|
33
|
Feasibility of economic analysis of Radiation Therapy Oncology Group (RTOG) 91-11 using Medicare data.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.75
|